Wednesday, Sep 28, 2022
International Finance
Healthcare

China-based Keya Medical secures $22 mn Series B+ funding

Keya Medical funding_IFM_Image
The funding round was led by global venture capital firm GGV Capital

China-based healthcare startup Keya Medical has secured around $22 million in its Series B+ funding round, the media reported.

The funding round for Keya Medicals was led by global venture capital firm GGV Capital.

Other investors that participated in the funding round for Keya Medicals include Kunlun Internet Intelligent Industrial Investment Fund, Shanghai Guofang FOF, Shanghai International Group (SIG), and Beijing-based life sciences-dedicated fund Alwin Capital.

Keya Medical, which develops AI-enabled medical imaging analysis products, claims to be the only Chinese approved by China’s National Medical Products Administration (NMPA) and America’s Food and Drug Administration (FDA).

According to reports, the startup will use the funds for research and development (R&D) of new products, global commercialisation of its existing products, as well as to expand in new markets.

Earlier this year, Keya Medical also raised around $14 million in an funding round which saw participation from Beijing Kunlun Tech and investment firm IDG Capital.

Last month, China-based biopharmaceutical company Antengene secured around $97 million funding in its Series C funding round.

Antengene is hematology and oncology-focused biopharmaceutical company with integrated drug discovery, clinical development, manufacturing and commercialisation anchored in the Asia Pacific regions and with a global layout.

The funding round for Antengene was led by Fidelity Management & Research Company. Other investors who also participated in the funding round include GL Ventures, GIC, Qiming Venture Partners, and Boyu Capital.

Reportedly, Antengene will use the funds to use the funds for the continuing clinical development of its pipeline of hematology and oncology therapies, expanding in-house research and development capabilities and strengthening the commercial infrastructures in APAC markets.

Leave a Comment

* By using this form you agree with the storage and handling of your data by this website.